150
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Circular RNA PGPEP1 induces colorectal cancer malignancy and immune escape

, , , & ORCID Icon
Pages 1743-1758 | Received 15 Aug 2022, Accepted 14 May 2023, Published online: 09 Jul 2023
 

ABSTRACT

Objective

Colorectal cancer (CRC) is a prevalent gastrointestinal tumor globally. Circular RNAs (circRNAs) have been identified as regulatory players in the pathogenesis of CRC. However, it is unclear whether hsa_circ_0050102 (circPGPEP1) affects the malignant progression and immune escape in CRC.

Methods

Bioinformatics analysis and circRNA in vivo precipitation experiments were performed to analyze and identify circRNAs that mediate immune escape in CRC. Using luciferase reporter assay, RIP, RNA pull-down assay, and FISH, the interaction between circPGPEP1, miR-515-5p, and nuclear factor of activated T-cell 5 (NFAT5) was identified. The functional role of circPGPEP1/miR-515-5p/NFAT5 axis in CRC anti-tumor immunity was investigated by co-culture assay, CFSE assay, and flow cytometry of CRC cells and T cells.

Results

circPGPEP1 was a stable circRNA that was highly expressed in CRC. Functionally, circPGPEP1 silencing not only effectively inhibited CRC cell proliferation, migration, EMT, and immune escape and promoted apoptosis in vitro, but also inhibited CRC tumor growth and immune escape in vivo. In terms of the regulatory mechanism, circIGF2BP3 competitively upregulated NFAT5 expression by sponging miR-515-5p. Furthermore, functional rescue experiments showed that circPGPEP1 acted in CRC by regulating the miR-515-5p/NFAT5 axis.

Conclusion

Collectively, circPGPEP1 exerts an oncogene role in CRC by regulating the miR-515-5p/NFAT5 axis.

Disclosure statement

No potential conflict of interest was reported by the authors.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All subjects was approved by the First Affiliated Hospital of Dalian Medical University.

Additional information

Funding

No funding was received

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.